Ascendis Pharma A/S (ASND) Stock
1 member of Congress disclosed 2 trades in ASND since 2018: 2 purchases and 0 sales, most recently Gary Palmer (purchase, Aug 6, 2018). Company insiders reported 2 open-market buys and 2 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
Which members of Congress traded Ascendis Pharma A/S (ASND)?
Most recent: Gary Palmer (purchase, Aug 6, 2018); records start Jul 12, 2018.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gary Palmer R-AL · House | 2018-08-06 | purchase | $1k – $15k |
| Gary Palmer R-AL · House | 2018-07-12 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all ASND political trades →Are Ascendis Pharma A/S insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 8, 26 | Bodenhoff Mads | SVP & PAO | SELL | 3.0K | $811K |
| Sep 2, 26 | Holtug Lars | Director | SELL | 236 | $62K |
| Aug 14, 26 | Bienaime Jean Jacques | Director | BUY | 1.1K | $270K |
| Aug 14, 26 | Bienaime Jean Jacques | Director | BUY | 900 | $222K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →ASND price chart
Powered by TradingViewWhat does Ascendis Pharma A/S do?
Ascendis Pharma is a global biopharmaceutical company headquartered in Copenhagen, Denmark, specializing in the development of innovative therapies using its proprietary TransCon technology platform. The company focuses on addressing unmet medical needs across endocrinology, rare diseases, and oncology. Its pipeline includes TransCon hGH for growth hormone deficiency, TransCon CNP for achondroplasia, and TransCon PTH for hypoparathyroidism, along with oncology candidates in development. Ascendis conducts clinical trials across the United States, Europe, and multinational markets, with strategic partnerships extending development efforts to Asia through entities like VISEN Pharmaceuticals in Greater China and collaborations in Japan. The company operates research facilities in Germany and offices throughout Europe and the United States, maintaining a commitment to improving treatment safety, efficacy, tolerability, and patient convenience through its innovative drug development approach.